EICHORCondition: Biliary Atresia · Sponsor: Intercept Pharmaceuticals
This study will evaluate the efficacy, safety and tolerability, as well as PK/PD of OCA in eligible pediatric participants with biliary atresia with successful hepatoportoenterostomy (HPE, also known as a Kasai portoenterostomy). The double-blind period comprises of 2 phases: dose titration phase and age expansion treatment phase.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Queensland Childrens Hospital | South Brisbane, Queensland, Australia | — |
| Women's and Children's Hospital | North Adelaide, South Australia, Australia | — |
| Royal Childrens Hospital | Parkville, Victoria, Australia | — |
| Alberta Childrens Hospital | Calgary, Alberta, Canada | — |
| Stollery Children's Hospital | Edmonton, Alberta, Canada | — |
| Children's Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | — |
| Guangzhou Women And Childrens Medical Center | Guangzhou, China | — |
| Children's Hospital of Fudan University | Shanghai, China | — |
| Childrens Hospital of Shanghai | Shanghai, China | — |
| Children's Hospital of Shanxi | Taiyuan, China | — |
| Queen Mary Hospital | Hong Kong, Hong Kong | — |
| Hadassah Medical Center | Jerusalem, Israel | — |
+ 12 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06121375